Assessment of real-world escalation to biologics in US patients with asthma
Bender B, Oppenheimer J, George M, Brown R, Patel A, Hill T, Boe A, Herrera EM, Dotiwala Z, Casciano J, Bernstein JA. Assessment of real-world escalation to biologics in US…
Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions
Oppenheimer J, Hoyte FCL, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma…
Mepolizumab reduces exacerbations in youths with eosinophilic asthma living in urban areas
Phenotype-directed mepolizumab therapy reduced the number of asthma exacerbations among children and adolescents with exacerbation-prone eosinophilic asthma who live in disadvantaged urban neighborhoods, researchers reported in The Lancet. “[I]n urban children…
Questionnaire survey for the assessment of the response to biologics in severe asthma at 4 months of treatment
Dear Colleagues, Interasma Scientific Network (INES) invite you to complete this survey, leaded by Prof. Angelica Tiotiu which aims to “identify 5 criteria to use in practice for the evaluation of…
Characterisation of the Australian Adult Population Living with Asthma: Severe – Exacerbation Frequency, Long-Term OCS Use and Adverse Effects
Kerry L Hancock, 1 Sinthia Bosnic-Anticevich, 2 , 3 , 4 John D Blakey, 5 , 6 Mark Hew, 7 , 8 Li Ping Chung, 9 Biljana Cvetkovski, 3 Scott Claxton, 10 Peter Del Fante, 11 Eve Denton, 7 , 8 Joe Doan, 12 Kanchanamala Ranasinghe, 13 , 14 Lucy Morgan, 15 , 16 , 17 Anita Sharma, 18 Peter K Smith, 19 Deb Stewart, 20 Philip J…
Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma
The Journal of Allergy and Clinical Immunology: In Practice Volume 10, Issue 6, June 2022, Pages 1545-1553.e2 MustafaAbdoMDaFraukePedersenPhDabAnneMarieKirstenMDbVeraVeithPhDaHeikeBillerMDaFrederikTrinkmannMDcdErikavon MutiusMDeMatthiasKoppMDfgGesineHansenMDhKlaus F.RabeMD, PhDaThomasBahmerMDai∗HenrikWatzMDb∗ALLIANCE study group Background Little is known about the relationship between…
Optimizing Asthma Outcomes: Difficult-to-Treat and Severe Asthma in Primary Care
Summary This webcast will address recent advances in asthma treatment which allow for greater individualization of therapy, particularly for patients with difficult-to-treat and severe asthma. Available therapies are highly effective…
Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study
Eur Respir J. 2022 Jun; 59(6): 2101733.Published online 2022 Jun 30. doi: 10.1183/13993003.01733-2021 Stacey N. Reinke,1,2,30Shama Naz,1,30Romanas Chaleckis,1,3Hector Gallart-Ayala,1Johan Kolmert,1,4Nazanin Z. Kermani,5Angelica Tiotiu,5,6David I. Broadhurst,2Anders Lundqvist,7Henric Olsson,8Marika Ström,9,10Åsa M. Wheelock,9,10Cristina Gómez,1,4Magnus Ericsson,11Ana R.…
Associations between comorbidities and annual incidence plus frequency of asthma exacerbation hospitalisation during the past year: data from CARN study
Research – Open Access Wenqiao Wang, Jiangtao Lin, Xin Zhou, Changzheng Wang, Mao Huang et al. BMC Pulmonary Medicine volume 22, Article number: 261 (2022) Abstract Purpose While asthma comorbidities are associated with higher health care utilisation, lower quality…
Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
Research – Open Access Jefferson Antonio Buendía, Diana Guerrero Patiño & Jorge Mario Sánchez Caraballo BMC Pulmonary Medicine volume 22, Article number: 257 (2022) Abstract Introduction Previous evidence has shown that fractional exhaled nitric oxide (FeNO) and eosinophil…